Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Healthcare: Are These Beaten-Down Clinical-Stage Biotechs Buys?

  • Broadcast in Finance
Industry Focus

Industry Focus

Featured Host
×  

Follow This Show

If you liked this show, you should follow Industry Focus.
h:899941
s:11009647
archived
Play
  • Host

Geron shares tumbled after J&J jilted them and Omeros  shares fell sharply following a clinical-trial update. Should you avoid these stocks, or are they bargain bin stocks worth buying? GERN OMER INCY

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled